Taligen Therapeutics Secures $10,000,000 Series B Funding Round

  • Feed Type
  • Date
    8/23/2010
  • Company Name
    Taligen Therapeutics
  • Mailing Address
    12635 East Montview Blvd Aurora, CO 80045
  • Company Description
    Taligen’s lead technology is directed at inhibiting factor B, an essential component in the amplification of complement activation. Inhibition of factor B down-regulates complement activation, thereby dampening the inflammatory response. Taligen’s second technology is able to target complement inhibitors specifically to sites where excessive complement activation is occurring, thereby controlling inflammation at a specific tissue site.
  • Website
    http://www.taligentherapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $10,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The company will use the funding to advance its first drug candidate toward initial human studies.
  • M&A Terms
  • Venture Investor
    Alta Partners
  • Venture Investor
    Clarus Ventures
  • Venture Investor
    Sanderling Ventures
  • Venture Investor
    High Country Venture

By posting a comment, you agree to our terms and conditions.